Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma
These results provide comprehensive evidence that ivosidenib is an effective treatment with a tolerable safety profile for this aggressive disease, supporting previous data (ClinicalTrials.gov NCT02989857).
Authors
- Rachna T. Shroff (ORCID: https://orcid.org/0000-0003-0066-2672)
- Camelia Gliser
- Robin Kate Kelley (ORCID: https://orcid.org/0000-0002-1984-2430)
- Hui Liu (ORCID: https://orcid.org/0000-0001-5973-3063)
- Yunyi Bian (ORCID: https://orcid.org/0000-0003-3864-1199)
- Milind M. Javle (ORCID: https://orcid.org/0000-0001-9158-0941)
- Maeve A. Lowery (ORCID: https://orcid.org/0000-0003-1354-7606)
- Gaëlle Saint‐Hilary (ORCID: https://orcid.org/0000-0003-1643-3348)
- Juan W. Valle (ORCID: https://orcid.org/0000-0002-1999-0863)
- Arndt Vogel (ORCID: https://orcid.org/0000-0003-0560-5538)
- Ghassan K. Abou‐Alfa (ORCID: https://orcid.org/0000-0002-1522-8054)
- Zhaoyang Teng (ORCID: https://orcid.org/0000-0001-9814-8713)
- Hua Zhang (ORCID: https://orcid.org/0000-0001-9518-740X)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Arizona (US)
- University of California, San Francisco (US)
- Trinity College Dublin (IE)
- Cornell University (US)
- Toronto General Hospital (CA)
- Princess Margaret Cancer Centre (CA)
- University of Manchester (GB)
- Medizinische Hochschule Hannover (DE)
- Cancer Research UK Manchester Institute (GB)
- Cholangiocarcinoma Foundation (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of Arizona Cancer Center
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100159
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Servier